OBJECTIVE:Postprandial hyperglycemia characterizes early type 2 diabetes. We investigated whether ameliorating postprandial hyperglycemia with acarbose would prevent or delay progression of diabetes, defined as progression to frank fasting hyperglycemia, in subjects with early diabetes (fasting plasma glucose [FPG] <140 mg/dl and 2-h plasma glucose > or =200 mg/dl). RESEARCH DESIGN AND METHODS: Two hundred nineteen subjects with early diabetes were randomly assigned to 100 mg acarbose t.i.d. or identical placebo and followed for 5 years or until they reached the primary outcome (two consecutive quarterly FPG measurements of > or =140 mg/dl). Secondary outcomes included measures of glycemia (meal tolerance tests, HbA(1c), annual oral glucose tolerance tests [OGTTs]), measures of insulin resistance (homeostasis model assessment [HOMA] of insulin resistance and insulin sensitivity index from hyperglycemic clamps), and secondary measures of beta-cell function (HOMA-beta, early- and late-phase insulin secretion, and proinsulin-to-insulin ratio). RESULTS:Acarbose significantly reduced postprandial hyperglycemia. However, there was no difference in the cumulative rate of frank fasting hyperglycemia (29% with acarbose and 34% with placebo; P = 0.65 for survival analysis). There were no significant differences between groups in OGTT values, measures of insulin resistance, or secondary measures of beta-cell function. In a post hoc analysis of subjects with initial FPG <126 mg/dl, acarbose reduced the rate of development of FPG > or =126 mg/dl (27 vs. 50%; P = 0.04). CONCLUSIONS:Ameliorating postprandial hyperglycemia did not appear to delay progression of early type 2 diabetes. Factors other than postprandial hyperglycemia may be greater determinants of progression of diabetes. Alternatively, once FPG exceeds 126 mg/dl, beta-cell failure may no longer be remediable.
RCT Entities:
OBJECTIVE: Postprandial hyperglycemia characterizes early type 2 diabetes. We investigated whether ameliorating postprandial hyperglycemia with acarbose would prevent or delay progression of diabetes, defined as progression to frank fasting hyperglycemia, in subjects with early diabetes (fasting plasma glucose [FPG] <140 mg/dl and 2-h plasma glucose > or =200 mg/dl). RESEARCH DESIGN AND METHODS: Two hundred nineteen subjects with early diabetes were randomly assigned to 100 mg acarbose t.i.d. or identical placebo and followed for 5 years or until they reached the primary outcome (two consecutive quarterly FPG measurements of > or =140 mg/dl). Secondary outcomes included measures of glycemia (meal tolerance tests, HbA(1c), annual oral glucose tolerance tests [OGTTs]), measures of insulin resistance (homeostasis model assessment [HOMA] of insulin resistance and insulin sensitivity index from hyperglycemic clamps), and secondary measures of beta-cell function (HOMA-beta, early- and late-phase insulin secretion, and proinsulin-to-insulin ratio). RESULTS:Acarbose significantly reduced postprandial hyperglycemia. However, there was no difference in the cumulative rate of frank fasting hyperglycemia (29% with acarbose and 34% with placebo; P = 0.65 for survival analysis). There were no significant differences between groups in OGTT values, measures of insulin resistance, or secondary measures of beta-cell function. In a post hoc analysis of subjects with initial FPG <126 mg/dl, acarbose reduced the rate of development of FPG > or =126 mg/dl (27 vs. 50%; P = 0.04). CONCLUSIONS: Ameliorating postprandial hyperglycemia did not appear to delay progression of early type 2 diabetes. Factors other than postprandial hyperglycemia may be greater determinants of progression of diabetes. Alternatively, once FPG exceeds 126 mg/dl, beta-cell failure may no longer be remediable.
Authors: Yash R Patel; M Sue Kirkman; Robert V Considine; Tamara S Hannon; Kieren J Mather Journal: J Diabetes Complications Date: 2016-11-12 Impact factor: 2.852
Authors: Tamara S Hannon; M S Kirkman; Yash R Patel; Robert V Considine; Kieren J Mather Journal: Diabetes Metab Res Rev Date: 2014-11 Impact factor: 4.876
Authors: Kieren J Mather; Ashley H Tjaden; Adam Hoehn; Kristen J Nadeau; Thomas A Buchanan; Steven E Kahn; Silva A Arslanian; Sonia Caprio; Karen M Atkinson; Melanie Cree-Green; Kristina M Utzschneider; Sharon L Edelstein Journal: Am J Physiol Endocrinol Metab Date: 2021-03-01 Impact factor: 4.310
Authors: Fianne L P Sips; Elin Nyman; Martin Adiels; Peter A J Hilbers; Peter Strålfors; Natal A W van Riel; Gunnar Cedersund Journal: PLoS One Date: 2015-09-10 Impact factor: 3.240
Authors: Erika Ibarra-Pastrana; Maria Del Carmen Candia Plata; Gerardo Alvarez; Mauro E Valencia Journal: Int J Endocrinol Date: 2012-07-17 Impact factor: 3.257
Authors: Suzanne Vl Moelands; Peter Lbj Lucassen; Reinier P Akkermans; Wim Jc De Grauw; Floris A Van de Laar Journal: Cochrane Database Syst Rev Date: 2018-12-28